Effect of WSP, a Chinese Herbal Formula, on Th17/Treg Ratio and HBeAg Seroconversion in Telbivudine-Treated HBeAg-Positive Chronic Hepatitis B Patients with High Baseline ALT Levels (20–30 Times the ULN)
Table 3
Viral and host responses (n, %).
Characteristics
Treatment (n = 34)
Control (n = 34)
t/χ2/z
P value
Viral response
HBV DNA negative rate
Week 12
16(47.1)
10(29.4)
2.242
0.134
Week 24
25(73.5)
16(47.1)
4.976
0.026
Week 36
28(82.4)
19(55.9)
5.581
0.018
Week 52
29(85.3)
21(61.8)
4.836
0.028
HBeAg seroclearance rate
Week 12
3(8.8)
1(2.9)
0.266
0.606
Week 24
11(32.4)
4(11.8)
4.191
0.041
Week 36
15(44.1)
9(26.5)
4.331
0.037
Week 52
21(61.8)
12(35.3)
4.769
0.029
Severity
HBeAg seroconversion rate
Week 12
0(0)
0(0)
-
-
Week 24
7(20.6)
1(2.9)
5.100
0.024
Week 36
11(32.4)
4(11.8)
4.191
0.041
Week 52
15(44.1)
7(20.6)
4.300
0.038
Host response
ALT normalization rate
Week 12
13(38.2)
8(23.5)
1.722
0.189
Week 24
31(91.2)
21(61.8)
8.173
0.004
Week 36
32(94.1)
23(67.7)
7.703
0.006
Week 52
32(94.1)
26(76.5)
4.221
0.040
Th17/Treg cells ratio
Week 12
0.63±0.30
0.49±0.20
2.264
0.027
Week 24
0.57±0.26
0.45±0.19
2.173
0.033
Week 36
0.53±0.19
0.42±0.22
2.206
0.031
Week 52
0.44±0.15
0.36±0.14
2.273
0.026
All values are expressed as mean ± SD or number (%). HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; ALT, alanine aminotransferase; Th, T helper cells; Treg, regulator T cells.
